<DOC>
	<DOCNO>NCT03022097</DOCNO>
	<brief_summary>This multiple dose , randomise , parallel , double blind , double dummy , multicentre multinational Phase III study determine efficacy safety Aclidinium bromide/Formoterol fumarate compare individual component placebo Aclidinium bromide compare Placebo administer patient stable Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>Study Patients With Stable COPD Assess Efficacy Safety Aclidinium Bromide/Formoterol Fumarate ( DUAKLIR )</brief_title>
	<detailed_description />
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>1 . Adult male nonpregnant , nonlactating female patient age ≥40 2 . Patients diagnosis COPD ( GOLD guideline , 2015 ) period least 6 month prior Visit 1 ( screen ) 3 . Patients moderate severe stable COPD ( Stage II Stage III , accord GOLD Guidelines 2015 ) Visit 1 : postbronchodilator FEV1 ≥30 % &lt; 80 % postbronchodilator FEV1/Forced vital capacity ( FVC ) &lt; 70 % 4 . Current former smoker smoke history ≥ 10 packyears 5 . Patients able perform repeatable pulmonary function test FEV1 accord American Thoracic Society ( ATS ) /European Respiratory Society ( ERS ) 2005 criterion Visit 1 ( screen ) 6 . 6 . Patients understand study procedure willing participate study indicate sign informed consent 1 . Involvement plan and/or conduct study ( applies AstraZeneca staff and/or site staff ) patient employ relative employee site sponsor . 2 . Previous enrolment randomisation present study 3 . History current diagnosis asthma 4 . Any respiratory tract infection ( include upper respiratory tract ) COPD exacerbation ( include mild COPD exacerbation ) within 6 week prior screen runin period 5 . Patients hospitalize COPD exacerbation ( emergency room visit longer 24 hour consider hospitalization ) within 3 month prior screen runin period 6 . Clinically significant respiratory condition COPD 7 . Patients Investigator 's opinion may need start pulmonary rehabilitation program study and/or patient started/finished within 3 month prior screen 8 . Use longterm oxygen therapy ( ≥15 hours/day ) 9 . Patient maintain regular day/night , waking/sleeping cycle include night shift worker 10 . Clinically significant cardiovascular condition 11 . Patients Type I uncontrolled Type II diabetes , uncontrolled hypoor hyperthyroidism , hypokalaemia , hyperadrenergic state , uncontrolled untreated hypertension 12 . Patients QT correct interval ( QTc ) use Fridericia formula ( QTcF ) ( QTc=QT/ Duration milliseconds two R peak two consecutive QRS complex ( RR1/3 ) &gt; 470 msec indicate centralised reading report assess Screening ( Visit 1 ) 13 . Patients clinically significant abnormality clinical laboratory test , ECG parameter ( QTcF ) physical examination Visit 1 ( screen ) 14 . Patients abnormal liver function test define Aspartate aminotransferase ( AST ) , Alanine aminotransferase ( ALT ) , total bilirubin ≥ 2.5 time upper limit normal range screen 15 . Patient know noncontrolled history infection human immunodeficiency virus and/or active hepatitis 16 . Patient history hypersensitivity reaction inhale anticholinergic drug , sympathomimetic amine , inhaled medication component thereof 17 . Patient know narrowangle glaucoma , symptomatic bladder neck obstruction , acute urinary retention , patient symptomatic nonstable prostatic hypertrophy 18 . History malignancy organ system ( include lung cancer ) , treat untreated , within past 5 year basal squamous cell skin cancer 19 . Any serious uncontrolled physical mental dysfunction 20 . Patients history ( within 2 year prior Visit 1 ( screen ) drug and/or alcohol abuse may prevent study compliance base Investigator judgment 21 . Patients unlikely cooperative comply study procedures 22 . Patients treat investigational drug within 30 day ( 6 halflives , whichever long ) prior screen 23 . Patients intend use concomitant medication permit protocol undergone require washout period particular prohibit medication 24 . Patients unable give consent , patient consent age guardianship , vulnerable patient 25 . Any condition , Investigator 's opinion , might indicate patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>